MIST
HEALTHCAREMilestone Pharmaceuticals Inc
AI Insight
What's Moving MIST Today?
No stock-specific AI insight has been generated for MIST yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.00$3.06
$1.30
Fundamentals
Market Cap$163M
P/E Ratio—
EPS$-0.64
Dividend Yield—
Dividend / Share—
ROE-456.9%
Profit Margin—
Debt / Equity—
Trading
Volume296K
Avg Volume (10D)—
Shares Outstanding124.5M
MIST News
21 articles- Milestone Pharmaceuticals (MIST) investors approve equity plan, elect board and ratify PwCStock Titan·Jun 15, 2026
- Milestone (MIST) Q1 2026 Earnings TranscriptMotley Fool·Jun 1, 2026
- Paroxysmal Supraventricular Tachycardia Market Analysis Report 2026-2036, Profiles of Leading Players - Medtronic, Boston Scientific, Abbott Laboratories, Milestone Pharmaceuticals, Sanofi, PfizerYahoo Finance·May 21, 2026
- Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Path To ProfitabilityYahoo Finance·May 15, 2026
- Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQYahoo Finance·May 14, 2026
- Milestone Pharmaceuticals Inc. Q1 2026 Earnings Call SummaryMoby·May 14, 2026
- Milestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...Yahoo Finance·May 13, 2026
- Why Milestone Pharmaceuticals Stock Wilted on WednesdayMotley Fool·May 13, 2026
- Milestone Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 13, 2026
- Milestone Pharmaceuticals Q1 2026 Earnings Call: Complete TranscriptYahoo Finance·May 13, 2026
- Milestone Pharmaceuticals shares plunge after CARDAMYST revenue misses expectations (MIST)Advfn·May 13, 2026
- Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 13, 2026
- Earnings Scheduled For May 13, 2026Yahoo Finance·May 13, 2026
- Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 13, 2026
- Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026Yahoo Finance·May 6, 2026
- Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVTGlobeNewswire Inc.·Apr 10, 2026
- Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 7, 2026
- Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 2, 2026
- Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National FormulariesYahoo Finance·Mar 31, 2026
- Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...Yahoo Finance·Mar 20, 2026
- Milestone Pharmaceuticals Q4 Earnings Call HighlightsMarketbeat·Mar 20, 2026
All 21 articles loaded
Price Data
Open$1.30
Previous Close$1.30
Day High$1.31
Day Low$1.27
52 Week High$3.06
52 Week Low$1.00
52-Week Range
$1.00$3.06
$1.30
Fundamentals
Market Cap$163M
P/E Ratio—
EPS$-0.64
Dividend Yield—
Dividend / Share—
ROE-456.9%
Profit Margin—
Debt / Equity—
Trading
Volume296K
Avg Volume (10D)—
Shares Outstanding124.5M
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular drugs. The company is headquartered in Montral, Canada.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—